Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
Chowdhury S, Oudard S, Uemura H, Joniau S, Dearden L, Capone C, Van Sanden S, Diels J, Hadaschik BA. Chowdhury S, et al. Among authors: diels j. Adv Ther. 2022 Jan;39(1):518-531. doi: 10.1007/s12325-021-01885-6. Epub 2021 Nov 19. Adv Ther. 2022. PMID: 34797506 Free PMC article. Clinical Trial.
Inverse Probability of Censoring Weighted Analysis to Adjust the Treatment Effect on Overall Survival for Subsequent Therapy: A Case Study in a Clinical Trial in Multiple Myeloma.
Thilakarathne P, Palumbo A, Diels J, Delforge M, van Sanden S, Mateos MV, Chirita O, Dimopoulos MA, van de Velde H, San Miguel JF. Thilakarathne P, et al. Among authors: diels j. Value Health. 2014 Nov;17(7):A546. doi: 10.1016/j.jval.2014.08.1770. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201769 Free article. No abstract available.
Comparison of Mean Overall Survival (OS) and Radiographic Progression Free Survival (RPFS) Based on Matching Adjusted Indirect Comparison of Abiraterone Acetate and Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Chemotherapy Naïve Patients.
Dearden L, Majer I, Heeg B, Liwing J, Sandstrom K, Diels J. Dearden L, et al. Among authors: diels j. Value Health. 2014 Nov;17(7):A616. doi: 10.1016/j.jval.2014.08.2170. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202160 Free article. No abstract available.
The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K, Carles J, Gschwend JE, Van Poppel H, Diels J, Brookman-May SD. Miller K, et al. Among authors: diels j. Eur Urol. 2018 Jul;74(1):17-23. doi: 10.1016/j.eururo.2017.08.035. Epub 2017 Sep 20. Eur Urol. 2018. PMID: 28939004 Clinical Trial.
146 results